| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.1 | 0.04 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.097 | 0.06 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.1 | 0.1 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.065 | 0.2 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.059 | 0.2 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.058 | 0.2 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.054 | 0.3 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.044 | 0.4 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.042 | 0.4 |